In Vitro Antifungal Activity of Epigallocatechin 3-O-Gallate against Clinical Isolates of Dermatophytes.
10.3349/ymj.2011.52.3.535
- Author:
Bong Joo PARK
1
;
Hideaki TAGUCHI
;
Katsuhiko KAMEI
;
Tetsuhiro MATSUZAWA
;
Suong Hyu HYON
;
Jong Chul PARK
Author Information
1. Department of Medical Engineering, Yonsei University College of Medicine, Seoul, Korea. parkjc@yuhs.ac
- Publication Type:Brief Communication ; Research Support, Non-U.S. Gov't
- Keywords:
Epigallocatechin 3-O-gallate;
Dermatophytes;
Microsporum canis;
Trichophyton mentagrophytes;
Trichophyton rubrum;
Susceptibility
- MeSH:
Antifungal Agents/*pharmacology;
Arthrodermataceae/*drug effects/isolation & purification;
Catechin/*analogs & derivatives/pharmacology;
Microbial Sensitivity Tests
- From:Yonsei Medical Journal
2011;52(3):535-538
- CountryRepublic of Korea
- Language:English
-
Abstract:
Previously, we reported that epigallocatechin 3-O-gallate (EGCg) has growth-inhibitory effect on clinical isolates of Candida species. In this study, we investigated the antifungal activity of EGCg and antifungal agents against thirty-five of dermatophytes clinically isolated by the international guidelines (M38-A2). All isolates exhibited good susceptibility to EGCg (MIC50, 2-4 microg/mL, MIC90, 4-8 microg/mL, and geometric mean (GM) MICs, 3.36-4 microg/mL) than those of fluconazole (MIC50, 2-16 microg/mL, MIC90, 4-32 microg/mL, and GM MICs, 3.45-25.8 microg/mL) and flucytosin (MIC50, MIC90, and GM MICs, >64 microg/mL), although they were less susceptible to other antifungal agents, such as amphotericin B, itraconazole, and miconazole. These activities of EGCg were approximately 4-fold higher than those of fluconazole, and were 4 to 16-fold higher than flucytosin. This result indicates that EGCg can inhibit pathogenic dermatophyte species. Therefore, we suggest that EGCg may be effectively used solely as a possible agent or combined with other antifungal agents for antifungal therapy in dermatophytosis.
